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Background:  Recent  studies  have  reported  that  concomitant  use of clopidogrel  with  proton-pump
inhibitors  (PPIs)  might  decrease  antiplatelet  effects  and  increase  the risk  of  adverse  outcomes  after
coronary  stenting.  However,  little  is known  about  the  difference  between  clopidogrel  and  ticlopidine
in  concomitant  use with  PPIs,  especially  within  the  Asian  population.
Methods:  We  retrospectively  analyzed  302 consecutive  patients  (248  males,  mean  age  66  ± 12 years)
undergoing  primary  stenting  for  acute  myocardial  infarction  from  July  2006  to  June 2010.  PPIs  were
administered  to 92% (278/302)  of the  patients.  The  patients  were  divided  into  two  groups on  the  basis  of
clopidogrel  (clopidogrel  group,  n  =  187)  or ticlopidine  (ticlopidine  group,  n = 91) with  PPI. Their  charac-
teristics,  medications,  and  30-day  clinical  outcomes  were  examined.
Results:  There  were  no  signiﬁcant  differences  in  30-day  major  adverse  cardiac  events  (cardiac  death,  non-
fatal myocardial  infarction,  and  deﬁnite  stent  thrombosis),  bleeding  events,  and  stroke  between  the  two
groups. The  discontinuation  of  clopidogrel  due  to  side  effects  was signiﬁcantly  less  frequent  than  that  of
ticlopidine  (1.1% vs  7.7%, p = 0.003,  respectively).
Conclusion:  Our  ﬁndings  suggest  that  concomitant  use of  clopidogrel  with  PPIs  might be safer  than
ticlopidine  with PPIs in  patients  undergoing  primary  stenting  for  acute  myocardial  infarction.
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Clopidogrel, an adenosine diphosphate receptor antagonist, is
etabolized by P450 enzymes including cytochrome P450 2C19
CYP2C19). It is widely prescribed to patients with acute coronary
yndrome or undergoing percutaneous coronary intervention (PCI).
ecent studies have suggested that proton pump inhibitors (PPIs)
ight reduce the antiplatelet effects of clopidogrel through inhi-
ition of CYP2C19 [1–4]. In addition, several reports have shown
hat concomitant use of clopidogrel and PPIs is associated with
n increased risk of adverse outcomes compared to use of clopi-
ogrel without PPIs [3,5]. However clinical implications have not
een consistent and are conﬂicting. The prevalence of CYP2C19
oss of function alleles has been shown to be much greater among
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Asians than among other populations [6],  therefore potential drug
interactions might be more apparent in Asian people.
On the other hand, ticlopidine, the predecessor of clopidogrel, is
also related to CYP2C19 for metabolic transformation [7].  The rate
of administration of ticlopidine has dramatically reduced due to
its adverse side effects such as neutropenia and thrombocytopenic
purpura [8].  There are few clinical reports on drug interactions
between ticlopidine and PPIs, and little is known about the differ-
ence between clopidogrel and ticlopidine in concomitant use with
PPIs. Therefore, the aim of this study was  to compare clinical out-
comes of Japanese patients with acute myocardial infarction (AMI)
between clopidogrel and ticlopidine in concomitant use with PPIs.
Methods
PatientsThis study included 302 consecutive patients undergoing pri-
mary percutaneous coronary intervention (PCI) for AMI  from July
2006 to June 2010 at our hospital. The diagnosis of AMI  (ST-
elevation MI  or non ST-elevation MI)  was based on severe chest
vier Ltd. All rights reserved.
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Table 1
Baseline clinical characteristics.
Clopidogrel group (n = 187) Ticlopidine group (n = 91) p-Value
Age, y 66 ± 12 65 ± 13 0.23
Male,  n (%) 152 (81) 74 (81) 0.99
Cardiovascular risk factors, n (%)
Diabetes 74 (40) 39 (43) 0.6
Hypertension 121 (65) 47 (52) 0.04
Dyslipidemia 82 (44) 31 (34) 0.12
Current smoker 79 (42) 44 (48) 0.34
Hemodialysis 2 (1) 2 (2) 0.46
CKD  (eGFR < 60 mL/min/1.73 m2) 66 (35) 20 (22) 0.02
PreviousMI 14 (7) 8 (9) 0.71
PriorPCI 10 (5) 8 (9) 0.27
PriorCABG 2 (1) 1 (1) 0.98
GU/DU history, n (%) 9 (5) 10 (11) 0.06
Medications at discharge, n (%)
Statin 174 (93) 85 (93) 0.91
ACEI/ARB 116 (62) 65 (71) 0.12
-Blocker 93 (50) 46 (51) 0.9
Ca-antagonist 33 (18) 10 (11) 0.15
Use of aspirine, n (%)
Aspirin 187 (100) 91 (100)
Use of PPI, n (%)
Lansoprazole 174 (93) 87 (96) 0.4
Others 13 (7) 4 (4)
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[KD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; MI,  myoca
rafting; GU, gastric ulcer; DU, duodenal ulcer; ACEI, angiotension-converting enzy
ain at rest lasting longer than 30 min, typical electrocardiographic
hanges (ST-segment elevation, new left bundle branch block,
r ST-segment depression), and/or elevation of creatine kinase
nd its isoenzyme to 2 times greater than the upper limit of
ormal. Patients with administration of ﬁbrinolytic agents, car-
iopulmonary arrest on arrival and without stenting were excluded
rom the study. All patients were treated with dual antiplatelet
herapy [aspirin and thienopyridine (clopidogrel or ticlopidine)].
owever, PPIs were not administered to 24 patients. Thus, a total
f 278 patients were treated with primary PCI for AMI  with con-
omitant use of thienopyridine and PPIs. The study subjects were
llocated to two  groups on the basis of clopidogrel with PPI (clopi-
ogrel group, n = 187) or ticlopidine with PPI (ticlopidine group,
 = 91).
edication and PCI procedure
Patients were treated with clopidogrel 75 mg  and aspirin 100 mg
nce daily in the clopidogrel group or ticlopidine 100 mg  twice
aily and aspirin 100 mg  once daily in the ticlopidine group. From
ctober 2007, clopidogrel has been available with health insurance
n Japan and was basically prescribed after its introduction.
Activated clotting time was maintained over 250 s during the
rocedure. Coronary stent placement (bare metal stent or drug
luting stent) was at the discretion of the PCI operator.
linical outcomes
Complications including major adverse cardiac events (MACE)
cardiac death, non-fatal MI,  and deﬁnite stent thrombosis) [9,10],
leeding events, stroke, and discontinuation of thienopyridine due
o drug side effects were investigated at 30-day follow up. Non-
atal MI  was deﬁned as an event with a new elevation in serum
reatine kinase and/or evolutionary ST elevation, development of
ew Q wave or left bundle branch block. Stroke was  deﬁned as per-
istent loss of neurological function developed after primary PCI
nd an acute lesion identiﬁed with magnetic resonance imaging.
leeding event was divided into major bleeding or minor bleed-
ng on the basis of thrombolysis in MI  (TIMI) bleeding classiﬁcation
major bleeding: intracranial hemorrhage or a > 5 g/dL decrease ininfarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass
hibitor; ARB, angiotension receptor II blocker; PPI, proton-pump inhibitor.
hemoglobin concentration or a > 15% absolute decrease in hemat-
ocrit; minor bleeding: observed blood loss (a > 3 g/dL decrease in
hemoglobin concentration or a > 10% decrease in hematocrit), no
observed blood loss (a > 4 g/dL decrease in hemoglobin concen-
tration or a > 12% decrease in hematocrit)] [11]. Deterioration of
liver function was  deﬁned as elevation of alanine aminotransferase,
aspartate aminotransferase, alkaline phosphatase, or direct biliru-
bin at least twice the upper normal value.
Statistical analysis
Data are presented as mean ± SD. Categorical variables are
expressed as count and percentages. Continuous data were com-
pared by using Student’s unpaired t test. Categorical data were
compared by means of 2 test. A p-value <0.05 was considered
statistically signiﬁcant. All analyses were performed with the SPSS
17.0 software package (SPSS, Chicago, IL, USA).
Results
Patient characteristics
Baseline clinical characteristics in all patients are shown in
Table 1. There were no signiﬁcant differences in age, sex, quali-
fying event, coronary vessel treated, and medication between the
two groups. With the exception of prevalence of hypertension
and chronic kidney disease deﬁned as estimated glomerular ﬁltra-
tion rate <60 mL/min/1.73 m2, no signiﬁcant differences were also
observed in cardiovascular risk factors at entry into the study. The
history of gastric ulcer or duodenal ulcer tended to be higher in the
ticlopidine group than the clopidogrel group, but this difference
was not statistically signiﬁcant (p = 0.06).
Lesion and procedural characteristics are shown in Table 2.
There were no signiﬁcant differences in culprit lesions, frequency
of intra-aortic balloon pump usage, angiographical results, or peak
serum creatine kinase level between the two  groups. Drug-eluting
stents were implanted for most patients in both groups, and the
rate was signiﬁcantly higher in the ticlopidine group (p = 0.002).
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Table  2
Lesion and procedural characteristics.
Clopidogrel group (n = 187) Ticlopidine group (n = 91) p-Value
Lesion site, n (%)
RCA 83 (44) 40 (44) 0.71
LAD 78 (42) 42 (46)
LCX  15 (8) 6 (7)
LMT 10  (5) 2 (2)
SVG  1 (1) 1 (1)
Multivessel disease, n (%) 110 (59) 45 (49) 0.14
TIMI  grade before PCI (0/1/2/3), n 91/37/41/18 47/13/24/7 0.59
TIMI  grade after PCI (0/1/2/3), n 1/1/12/173 0/0/9/82 0.57
PeakCK (IU/L) 2958 ± 2568 3189 ± 2800 0.49
IABP,  n (%) 27 (14) 10 (11) 0.42
Stent  type, n (%)
DES 157 (84) 88 (97) 0.002
BMS  30 (16) 3 (3)
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MCA, right coronary artery; LAD, left anterior descending artery; LCX, left circumﬂex 
nfarction; PCI, percutaneous coronary intervention; CK, creatine kinase; IABP, intra
linical outcomes
There were no signiﬁcant differences in the occurrence of 30-
ay MACE, bleeding events, and stroke between the two groups
Table 3). The discontinuation of clopidogrel was  signiﬁcantly less
requent than that of ticlopidine (1.1% vs 7.7%, p = 0.003). The causes
f thienopyridine discontinuation were skin disorder (rash) and
eterioration of liver function. No patients developed neutropenia
r thromobocytopenia. One patient had skin rash, and one patient
ad deterioration of liver function in the clopidogrel group. Four
atients had skin rash, and three patients incurred deterioration of
iver function in the ticlopidine group.
iscussion
To date, the difference between clopidogrel and ticlopidine in
oncomitant use with PPIs has not been clearly elucidated. We
nvestigated early outcomes after primary PCI in Japanese patients
ith AMI  between clopidogrel and ticlopidine in concomitant use
ith PPIs. Our study has produced a number of important ﬁnd-
ngs. First, there were no signiﬁcant differences in the occurrence
f MACE, stroke, and bleeding between concomitant use of clopido-
rel with PPIs and ticlopidine with PPIs in AMI  patients undergoing
rimary coronary stenting. Second, the discontinuation of clopi-
ogrel was signiﬁcantly less frequent than that of ticlopidine in
oncomitant use with PPIs.
Clopidogrel combined with aspirin in patients undergoing PCI
as been recommended because of its beneﬁcial effects on reducing
ardiovascular events [12–14].  It is well known that gastrointesti-
al hemorrhage is the most common serious bleeding complication
rom antiplatelet therapy [15], especially in acute coronary syn-
rome patients [16]. Therefore PPIs are often prescribed to
void gastrointestinal tract bleeding while taking dual antiplatelet
able 3
0-Day clinical outcomes.
Clopidogrel group (n = 187) 
n  (%) 
MACE 9 (4.8) 
Death 5 
Non  fatal MI  4 
Stent thrombosis 4 
Stroke 2 (1.1) 
Bleeding event 7 (3.7) 
Major 5 
Minor 2 
Discontinuation of the drug 2 (1.1) 
ACE, major adverse cardiac event; MI,  myocardial infarction.; LMT, left main trunk; SVG, saphenous vein graft; TIMI, thrombolysis in myocardial
 balloon pump; BMS, bare metal stent; DES, drug eluting stent.
therapy. Recent studies, however, have suggested that PPIs might
reduce the antiplatelet effects of clopidogrel through inhibition of
hepatic cytochrome CYP2C19 [1,2,17–19]. In addition, concomitant
use of clopidogrel and PPIs is associated with an increased risk of
adverse outcomes compared with use of clopidogrel without PPIs
[3,5]. In contrast, several studies have reported PPI use is not associ-
ated with an increased risk of cardiovascular events or mortality in
patients with administration of clopidogrel [4,20,21]. To date, the
clinical outcomes of various studies have shown conﬂicting results.
A large randomized trial has showed that there is no clinically
relevant cardiovascular interaction between PPIs and clopidogrel
whereas prophylactic use of a PPI reduces the rate of upper gas-
trointestinal bleeding [20]. A major limitation of the study was
that 94% of the study population was white and CYP2C19 polymor-
phisms were not considered. The genotype of this enzyme has been
classiﬁed into three groups: rapid extensive metabolizer, inter-
mediate metabolizer, and poor metabolizer. There are genetically
inter-ethnic differences in the frequencies of poor metabolizers of
CYP2C19: 2.5% in the white American, 2.0% in the African American,
3.5% in the white European, 19.8% in the Chinese-Ham popula-
tion, and 18.0–22.5% in the Japanese population [6].  Because of
the much greater prevalence of CYP2C19 loss of function alleles
among Asians compared to the other populations, the inﬂuence of
drug interactions might be more apparent in Asian people. A Tai-
wanese population-based study has reported that the concomitant
use of clopidogrel and PPIs is associated with an increased risk of re-
hospitalization and mortality in patients undergoing PCI [22]. In the
light of CYP2C19 polymorphisms, a nationwide population study
to investigate the inﬂuences of concomitant use of thienopyridine
with PPI would be necessary.
On the other hand, a recent meta-analysis reported that summa-
rized information from genetic association studies indicated that
CYP2C19 had no major impact on the clinical efﬁcacy of clopidogrel
Ticlopidine group (n = 91) p-Value
n (%)
6 (6.6) 0.54
4
2
2
3 (3.3) 0.19
2 (2.1) 0.49
2
0
7 (7.7) 0.003
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23]. One metabolomic analysis suggests that clopidogrel is metab-
lized primarily by other enzymes but not by CYP2C19 [24]. There
ight be no racial difference relating to effect of clopidogrel.
We found that early outcomes after primary PCI in Japanese
atients with AMI  and concomitant use of clopidogrel and PPI
ere not signiﬁcantly different from that of ticlopidine and PPI,
nd that the discontinuation of clopidogrel was signiﬁcantly less
requent than that of ticlopidine. The safety and tolerability of
lopidogrel has been found to be superior to that of ticlopidine.
n addition, clopidogrel and ticlopidine have shown comparable
fﬁcacy with regard to cardiac events at 1-month after success-
ul stenting [8].  Consistent with this previous ﬁnding, we showed
hat clopidogrel and ticlopidine in concomitant use with PPIs
ave equivalent effect regarding 30-day MACE in AMI  patients
ndergoing primary stenting. With regard to stent thrombosis,
he frequency in this study was about 2.1% in both groups.
ompared to a large clinical trial (HORIZONS-AMI), the rate of
tent thrombosis in HORIZONS-AMI trial was little different from
hat in this study [25]. We  also demonstrated superiority of
lopidogrel in safety and tolerability in concomitant use with
PIs.
Chronic kidney disease is associated with increased risk of car-
iovascular events in patients with acute coronary syndrome. In
atients with AMI  treated with PCI, estimated creatinine clearance
emains an independent predictor of short- and long-term mor-
ality [26]. Given that the incidence of chronic kidney disease in
he clopidogrel group was signiﬁcantly higher compared to the
iclopidine group, this difference potentially inﬂuences the clinical
utcomes. However, the occurrence of MACE was not signiﬁcantly
ifferent between the two groups.
Regarding the stent type, the rate of bare-metal stent use in the
lopidogrel group was higher than that in the ticlopidine group.
owever analysis without the patients implanted with a bare-
etal stent also led to similar results.
There are several limitations to our study. First, we could not
btain sufﬁcient data of the patients without PPIs. It would have
een a better investigation if we could have analyzed 4 groups that
ncluded a control group. However PPIs are usually administered to
igh-risk patients such as AMI, therefore this study seems to reﬂect
he real world. Second, because this single center study is retro-
pective, the study population consisted of consecutive patients
nd was relatively small and different in two groups. Large multi-
enter clinical investigations, especially in the Asian population, are
equired to address these issues. However, this is the ﬁrst clinical
utcome study in Japanese patients with AMI  comparing clopido-
rel with PPI and ticlopidine with PPI. It would be of beneﬁt to
ccumulate data regarding these speciﬁc problems in the Asian
opulation.
In conclusion, our ﬁndings suggest that concomitant use of
lopidogrel with PPI might be safer in patients with AMI  under-
oing primary coronary stenting compared to that of ticlopidine
ith PPI.
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